Skip to main content

Table 1 Three-year OS and DFS rates for ENB

From: Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients

Characteristic

Total n (%)

3-year

3-year

DFS

P

OS

P

Gender

 Male

111 (64.2)

58.4%

 

66.1%

 

 Female

67 (37.6)

57.0%

0.640

64.7%

0.366

Lymph node metastasis

 (+)

21 (11.2)

33.4%

 

55.8%

 

 (−)

166 (88.8)

59.4%

0.033

67.8%

0.130

Distant metastasis

 (+)

24 (12.8)

34.4%

 

35.3%

 

 (−)

163 (87.2)

60.9%

0.030

70.3%

0.014

Stage

 A

23 (12.5)

74.5%

 

91.3%

 

 B

48 (26.1)

76.1%

 

91.2%

 

 C

113 (61.4)

45.0%

0.000

49.5%

0.000

Treatment

Surgery

 Yes

148 (79.1)

58.9%

 

72.0%

 

 No

39 (20.9)

47.4%

0.038

45.7%

0.000

Extent of resection

 Gross total

106 (77.4)

72.5%

 

90.1%

 

 Subtotal

31 (22.6)

31.4%

0.000

46.8%

0.000

RT

 Yes

153 (81.8)

65.4%

 

70.8%

 

 No

34 (18.2)

22.7%

0.000

49.1%

0.021

CT

 Yes

37 (19.8)

67.4%

 

69.1%

 

 No

150 (80.2)

54.3%

0.162

66.0%

0.472

S + RT ± CT

 Yes

117 (62.6)

69.0%

 

77.1%

 

 No

70 (37.4)

37.1%

0.000

49.8%

0.000

S + RT

 Yes

88 (47.1)

66.5%

 

76.0%

 

 No

99 (52.9)

47.8%

0.019

57.9%

0.011

S + RT ± CT

 S + RT

88 (75.2)

66.5%

 

76.0%

 

 S + RT + CT

29 (24.8)

75.3%

0.283

80.6%

0.589

Recurrence

 Yes

62 (33.2)

14.1%

 

41.0%

 

 No

125 (66.8)

81.6%

0.000

82.8%

0.000

  1. S surgery, CT chemotherapy, RT radiotherapy, Bold indicates significant values